Biospring Partners is a dedicated, tech-enabled
pharma services growth equity firm

We invest in technology-enabled, EBITDA-positive B2B pharma services
businesses in areas including outsourced complex biomanufacturing
and outsourced clinical trials services.

Investment Themes

Outsourced Complex Biomanufacturing (CDMO) Outsourced Clinical Trial Services Digital Transformation

Outsourced Complex Biomanufacturing

Outsourced Clinical Trial Services

Digital Transformation

Our Approach

We focus exclusively on pharma services — deploying a hands-on approach to value creation and leveraging deep thematic research, an experienced operating team, and a proprietary sourcing platform. Our platform supports management teams with functional expertise across commercial, technical, and financial operations. We build conviction through years of direct engagement with biopharma, giving us a differentiated view into where the industry is heading—and what’s best positioned to serve patients. 

ef1c260beb3bc03b93f8cab0304a6a12

Biospring leverages our thematic work to identify high
potential companies and build multi-year relationships with management.

news and insights

Latest activity from Biospring and our portfolio

August 07, 2025

Biospring Backs CenExel; PathAI Expands Offering Post FDA Approval

April 14, 2025

Biospring Interview with Britt Harris (UTIMCO)

April 11, 2024

Primer: Radiopharma Overview